Tenderwize
Wróć do wyszukiwania

Non-exclusive discount agreement for Denosumab (Xgeva) products

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2027 · 342 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The structured data shows a submission deadline of 2027-07-31, while the notice text states the first participation dea...

Participation documents must be downloaded from the DTVP project room after access approval, but the annexes themselves...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements under §130a(8) SGB V for Denosumab/Xgeva products.
  • Products covered: Xgeva-branded products, biosimilars referencing the original Xgeva product, and corresponding import medicines.
Pokaż pełne podsumowanie

Open-house notice for non-exclusive discount agreements under §130a(8) SGB V for Denosumab/Xgeva-related products (including biosimilars and corresponding imports). The procedure is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no exclusivity. Documents are available via DTVP, but the extracted procurement documents were not provided beyond the TED XML notice, so document-specific annexes were not analyzed.

Ryzyka

The structured data shows a submission deadline of 2027-07-31, while the notice text states the first participation dea...

Participation documents must be downloaded from the DTVP project room after access approval, but the annexes themselves...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of §4(18) AMG for the offered medicines.
  • The company must have its seat in Germany, another EU Member State, or another EEA Contracting State for the relevant medicines.

Eligibility

  • Submission of the completed declaration of no exclusion grounds is required.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive discount agreement for Denosumab (Xgeva) products

Supply lot for a non-exclusive discount agreement under §130a(8) SGB V covering medicinal products with the active substance Denosumab, limited to Xgeva-branded products, biosimilars referencing Xgeva, and corresponding import medicines. Open-house model; no exclusivity and no minimum purchase quantity guaranteed. Scope and lot information come from structured data and XML notice.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Aug 2026 - May 2027

Kategoria

Pharmaceutical products

Termin

Deadline Jul 31, 2027

Szczegóły zamówienia

Data publikacji
05 Jul 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
464454-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3